Health Reporter Posted May 17 Report Share Posted May 17 Br J Nutr. 2023 May 18:1-33. doi: 10.1017/S0007114523001198. Online ahead of print.ABSTRACTBACKGROUND & OBJECTIVE: The study aimed to assess the total prevalence of functional gastrointestinal disorders (FGIDs), and separately, irritable bowel syndrome (IBS) among adults and to determine their potential association with fructose consumption.MATERIALS & METHODS: Data from the Hellenic National Nutrition and Health Survey (HNNHS) were included (3798 adults; 58.9% females). Information regarding FGID symptomatology was assessed using self-reported physician diagnosis questionnaires the reliability of which were screened using the ROME III, in a sample of the population. Fructose intake was estimated from 24 hour recalls and the MedDiet score was used to assess adherence to the Mediterranean diet.RESULTS: The prevalence of FGID symptomatology was 20.2%, while 8.2% had IBS (representing 40.2% of total FGID). The likelihood of FGID were 28% higher (95%CI: 1.03-1.6) and of IBS 49% (95%CI: 1.08-2.05) in individuals with higher fructose intake than with lower intake (3rd tertile compared to 1st). When area of residence was accounted for, individuals residing in the Greek islands, had a significantly lower probability of FGID and IBS compared to those residing in Mainland and the main Metropolitan areas, with Islanders also achieving a higher MedDiet score and lower added sugar intake, comparatively to inhabitants of the main metropolitan areas.CONCLUSIONS: FGID and IBS symptomatology was most prominent among individuals with higher fructose consumption, and this was most conspicuous in areas with a lower Mediterranean diet adherence, suggesting that the dietary source of fructose rather than total fructose should be examined in relation to FGID.PMID:37197939 | DOI:10.1017/S0007114523001198View the full article Link to comment Share on other sites More sharing options...
Recommended Posts